Login to Your Account



The Data Mouse that Aurora'd: EntreMed Preclinicals Uplifting

By Randy Osborne
Staff Writer

Tuesday, November 27, 2012
Published results from preclinical work with the company's oral Aurora A angiogenic kinase inhibitor boosted shares of EntreMed Inc., leaving the stock (NASDAQ:ENMD) to close Monday at $1.73, up 34 cents, or 24.5 percent, after trading as high as $1.99.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription